Spark Therapeutics (NASDAQ:ONCE)‘s stock had its “buy” rating reissued by stock analysts at Barclays in a research note issued to investors on Wednesday. They presently have a $54.00 price objective on the biotechnology company’s stock. Barclays’ target price indicates a potential upside of 17.62% from the company’s current price.

Other equities analysts have also issued research reports about the stock. BMO Capital Markets set a $89.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Tuesday, October 10th. Cowen reiterated a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Jefferies Group reiterated a “buy” rating and set a $95.00 price target on shares of Spark Therapeutics in a report on Tuesday, October 10th. Cantor Fitzgerald reiterated a “buy” rating and set a $105.00 price target (up previously from $94.00) on shares of Spark Therapeutics in a report on Tuesday, October 10th. Finally, Goldman Sachs Group reiterated a “buy” rating and set a $111.00 price target on shares of Spark Therapeutics in a report on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and sixteen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $79.14.

Shares of Spark Therapeutics (ONCE) traded up $1.15 during trading on Wednesday, reaching $45.91. 1,895,314 shares of the company’s stock were exchanged, compared to its average volume of 481,118. Spark Therapeutics has a 1 year low of $41.06 and a 1 year high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company had revenue of $1.90 million during the quarter, compared to analyst estimates of $1.40 million. During the same quarter in the prior year, the business earned ($1.07) EPS. The business’s quarterly revenue was up 45.8% on a year-over-year basis. equities research analysts expect that Spark Therapeutics will post -7.6 EPS for the current fiscal year.

In other Spark Therapeutics news, insider Daniel Faga sold 1,500 shares of Spark Therapeutics stock in a transaction on Tuesday, September 19th. The shares were sold at an average price of $85.00, for a total value of $127,500.00. Following the completion of the sale, the insider now directly owns 1,500 shares of the company’s stock, valued at $127,500. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction on Tuesday, September 26th. The shares were sold at an average price of $86.16, for a total transaction of $430,800.00. Following the completion of the sale, the insider now directly owns 215,000 shares of the company’s stock, valued at $18,524,400. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,068,809 shares of company stock worth $89,809,385. 7.30% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cornerstone Capital Management Holdings LLC. increased its stake in Spark Therapeutics by 3.2% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 11,089 shares of the biotechnology company’s stock valued at $662,000 after purchasing an additional 342 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares in the last quarter. Teachers Advisors LLC increased its stake in Spark Therapeutics by 1.9% in the first quarter. Teachers Advisors LLC now owns 34,534 shares of the biotechnology company’s stock valued at $1,842,000 after purchasing an additional 650 shares in the last quarter. California Public Employees Retirement System increased its stake in Spark Therapeutics by 2.1% in the second quarter. California Public Employees Retirement System now owns 39,100 shares of the biotechnology company’s stock valued at $2,336,000 after purchasing an additional 800 shares in the last quarter. Finally, Great West Life Assurance Co. Can increased its stake in Spark Therapeutics by 47.3% in the third quarter. Great West Life Assurance Co. Can now owns 3,939 shares of the biotechnology company’s stock valued at $351,000 after purchasing an additional 1,264 shares in the last quarter. 94.94% of the stock is owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Spark Therapeutics’ (ONCE) “Buy” Rating Reaffirmed at Barclays” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/13/spark-therapeutics-once-buy-rating-reaffirmed-at-barclays.html.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.